SLITRK6 and renal pelvis/ureter urothelial carcinoma: Mir et al. [14] demonstrated that SLITRK6 expression is significantly higher in UTUC than in bladder carcinoma at both the mRNA and protein levels, positioning it as a promising therapeutic target for UTUC.